Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Time to Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw strong trading volume on Monday . 7,007 shares traded hands during trading, an increase of 41% from the previous session’s volume of 4,973 shares.The stock last traded at $17.26 and had previously closed at $17.12.

Wall Street Analyst Weigh In

AAPG has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective on the stock. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target for the company. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Finally, BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat.com, Ascentage Pharma Group International has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Down 0.3%

The firm’s 50-day moving average price is $20.77 and its 200-day moving average price is $23.96. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The firm had revenue of $24.72 million for the quarter. Research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the third quarter worth about $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. XY Capital Ltd lifted its position in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares in the last quarter. Finally, UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.